Microprosthetic Implant for the Treatment of Erectile Dysfunction

Matt Schwartz and Robert DouglasAdvisor – Dr. Franz Baudenbacher

Thesis

• A microprosthetic drug delivery implant has the potential to provide a biomimetic treatment option for erectile dysfunction. –Minimally invasive– Patient compliance– Targeted drug release and control

Erectile Dysfunction Background

• Erectile Dysfunction (ED)– Prevalence in men 40-70 = 52%1

– Current treatment options• Prescription oral pills• Injection therapy• Penile prosthetics

– Drug therapy market size• $3.1 billion in 2005• Estimated growth of 6.5% annually through 20102

Codman 3000 and IsoMed Pumps

• Refillable drug delivery• No power supply• Pain management and chemotherapy• Constant flow, different models• Modify with trigger mechanism, one way

valve, and power supply• 510k approval

Drug Selection and Flow

• Papaverine hydrochloride plus phentolamine• Concentration of 50 mg/mL• Expected dosage of 10 mg = .2 mL– Less than with injection– 10mg*(1mL/50mg) = .2 mL

• 50 mL reservoir– 250 doses per refill– 50 mL * (1 dose/.2 mL) = 250 doses

Prototype Fabrication Materials

Prototype Fabrication

Prototype Valve Fabrication

References1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB.

Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. Urology 1994; 151: 54-61.

2. Elder, Melissa. Men’s Health: The Worldwide Market for Current and Emerging Drug Therapies, 2nd ed. Kalorma Information. May 2006.

3. Robert C. Dean, MD and Tom F. Lue, MD. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am. 2005 November; 32(4): 379-v.

4. “Codman 3000.” Codman Pumps. 15 Oct. 2009. Web. <http://www.codman.com/DePuy/products/Products/neuromodulation/pump/index.html>.

5. Sacral Plexus of the Right Side. Gray’s Anatomy.